M. Nocaudie

Advances in diagnostic practices affect thyroid cancer incidence in France.

M. Schlumberger, J. Orgiazzi, F. de Vathaire, 2004, European journal of endocrinology.

Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal.

G. de Pouvourville, M. Schlumberger, C. Corone, 2007, European journal of endocrinology.

Somatostatin analogs for the localization and preoperative treatment of an adrenocorticotropin-secreting bronchial carcinoid tumor.

X. Bertagna, X. Marchandise, J. Epelbaum, 1994, The Journal of clinical endocrinology and metabolism.

Comparison of technetium-99m methoxyisobutylisonitrile and gallium-67 citrate scanning in the assessment of lymphomas

D. Huglo, X. Marchandise, E. Wattel, 1995, European Journal of Nuclear Medicine.

Scintiscans and carcinoid tumors.

D. Huglo, F. Pattou, X. Marchandise, 1994, Surgery.

Chromogranin A assay and (131)I-MIBG scintigraphy for diagnosis and follow-up of pheochromocytoma.

D. Huglo, F. Pattou, X. Marchandise, 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.

V. Rohmer, P. Caron, S. Dejager, 2005, The Journal of clinical endocrinology and metabolism.

Somatostatin receptor imaging in somatotroph and non‐functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide

G. Sassolas, X. Marchandise, F. Borson‐Chazot, 1997, Clinical endocrinology.

[Preoperative localization of parathyroid lesions with Tc-99m-MIBI/iodine 123].

D. Huglo, X. Marchandise, C. Proye, 1996, Presse medicale.

Somatostatin receptor scintigraphy to predict the clinical evolution and therapeutic response of thyroid-associated ophthalmopathy

X. Marchandise, E. Itti, J. Wemeau, 1999, European Journal of Nuclear Medicine.